


cm

We claim:

1. A compound of formula (I)



(I)

PS 10 wherein

PG  $R_1$  represents a hydrogen atom or a  $C_{1-6}$  alkyl group;

$R_2$  represents a hydrogen atom or a  $C_{1-6}$  alkyl group;

$R_3$  represents a hydrogen atom;

$R_4$  represents a hydrogen atom or a  $C_{1-3}$  alkyl group;

PS 15 ~~and~~ pharmaceutically acceptable salts and solvates thereof.

2. A compound according to claim 1 wherein in the formula (I)  $R_1$  represents a hydrogen atom or a  $C_{1-3}$  alkyl group.

- 20 3. A compound according to claim 1 wherein in the formula (I)  $R_2$  represents a hydrogen atom or a  $C_{1-3}$  alkyl group.

4. A compound according to claim 1 wherein in the formula (I)  $R_2$  represents a  $C_{1-3}$  alkyl group.

25

5. A compound according to claim 1 wherein in the formula (I)  $R_4$  represents a  $C_{1-3}$  alkyl group.

30

~~6. N-Methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulphonamide and pharmaceutically acceptable salts and solvates thereof.~~

35

~~7. N,N-Dimethyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulphonamide and pharmaceutically acceptable salts and solvates thereof.~~

8. N-Ethyl-3-(4-piperidinyl)-1H-indole-5-ethanesulphonamide and pharmaceutically acceptable salts and solvates thereof.

9. N-Methyl-3-(4-piperidinyl)-1H-indole-5-ethanesulphonamide and pharmaceutically acceptable salts and solvates thereof.

10. 3-(1-Methyl-4-piperidinyl)-1H-indole-5-ethanesulphonamide and pharmaceutically acceptable salts and solvates thereof.

11. A pharmaceutical composition which comprises an effective amount of at least one compound of formula (I) as defined in Claim 1 or a pharmaceutically acceptable salt or solvate thereof together with one or more pharmaceutically acceptable carriers or excipients.

12. A pharmaceutical composition according to Claim 11 adapted for oral, parenteral or intranasal administration.

13. A pharmaceutical composition according to Claim 11 which is formulated in unit dosage form comprising 0.1mg to 100mg of active ingredient.

14. A pharmaceutical composition according to Claim 12 which is formulated in unit dosage form comprising 0.1mg to 100mg of active ingredient.


15. A method of treating a human susceptible to or suffering from migraine cluster headache, chronic paroxysmal hemicrania or headache associated with vascular disorders which comprises administering an effective amount of a compound of formula (I) as defined in Claim 1 or a pharmaceutically acceptable salt or solvate thereof.

16. A method of treating a human susceptible to or suffering from migraine, cluster headache, chronic paroxysmal hemicrania or headache associated with vascular disorders which comprises administering a pharmaceutical composition according to Claim 11.

14


17. A method of treating a human susceptible to or suffering from migraine, cluster headache, chronic paroxysmal hemicrania or headache associated with vascular disorders which comprises administering a pharmaceutical composition according to claim 12.<sup>13</sup>

18. A compound of formula (II)




wherein  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  are as defined in Claim 1.

19. A compound of formula (V)



wherein  $R_3$  and  $R_4$  are as defined in Claim 1

20. A compound of formula (X)



wherein  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  are as defined in Claim 1.

add  
add B2